Bloomberg and other sources are reporting that Johnson & Johnson has agreed to pay the U.S. $1 billion to settle the U.S. Attorney’s marketing probe. Read the full report here. Criminal please still may come in this case.
Risperdal was once J&J’s biggest selling drug. It was an anti-psychotic drug approved for use in psychotic disorders, such as schizophrenia. J&J began marketing it for off-label uses, such as bipolar disorder, dementia, mood and anxiety disorders and other unapproved uses.